Side-by-side · Research reference
CartalaxvsChonluten
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED10/32 cited
BAnimal-MechanisticHUMAN-REVIEWED8/38 cited
Cartalax
Bioregulator Peptide · Khavinson School
SQ · Protocol Unspecified
Chonluten
Khavinson Bioregulator · Bronchial Mucosa
Oral · Sublingual · Per Protocol
01Mechanism of Action
Parameter
Cartalax
Chonluten
Primary target
Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023
Bronchial epithelial cells and respiratory mucosa tissue complexes
Pathway
Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023
Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022
Downstream effect
Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023Povorozniuk 2007
Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022
Feedback intact?
—
—
Origin
Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007
Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology
Antibody development
—
—
02Dosage Protocols
Parameter
Cartalax
Chonluten
Animal model dose
Unspecified (cartilaginous tissue extract protocol)
Rat study; extract preparation details not indexed in available abstracts.
—
Human dosing
Not established in PubMed-indexed literature
Russian-tradition protocols exist but lack peer-reviewed Western validation.
—
Evidence basis
Animal mechanistic studies only
In vitro mechanistic
Typical protocol dose
—
10–20 mg / day
Russian bioregulator tradition dosing; not standardized in Western literature.
Frequency
—
Once or twice daily
Route
—
Oral (capsule) or sublingual
Sublingual claimed for enhanced bioavailability; not validated.
Duration
—
10–30 days per cycle
Traditional Khavinson protocol; cyclic administration common.
Clinical validation
—
None (PubMed indexed)
03Metabolic / Fat Loss Evidence
Parameter
Cartalax
Chonluten
Fat loss evidence
None — primary target is cartilage and bone tissue, not adipose
—
04Side Effects & Safety
Parameter
Cartalax
Chonluten
Documented adverse effects
None reported in indexed animal studies
—
Human safety data
Not available in PubMed-indexed literature
—
Documented adverse events
—
No published safety data in PubMed-indexed literature
Theoretical risks
—
Peptide hypersensitivity, GI intolerance (uncharacterized)
Drug interactions
—
Unknown — no pharmacokinetic studies available
Pregnancy / lactation
—
No data — avoid
Absolute Contraindications
Cartalax
- ·Unknown due to lack of human clinical trial data
Chonluten
- ·Known hypersensitivity to peptide components
Relative Contraindications
Cartalax
- ·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)
Chonluten
- ·Pregnancy and lactation (insufficient data)
- ·Active malignancy (theoretical bioregulator concern)
05Administration Protocol
Parameter
Cartalax
Chonluten
1. Route
Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.
Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.
2. Frequency
Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.
Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.
3. Storage
Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.
Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.
4. Timing
—
Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.
5. Cycle protocol
—
10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.